When shoppers are already in pain, navigating the huge selection of products in the over- the-counter (OTC) pain reliever aisle can feel overwhelming.
There’s a lot to choose from, and while different medicines might treat similar ailments, shoppers should be aware that some OTC pain relievers could be a better choice for them based on their personal risk factors or other medications they are already taking.
To help inform and empower shoppers’ decision-making at the time of purchase, the Consumer Healthcare Products Association Educational Foundation (CHPAEF) — in partnership with healthcare companies Haleon (formerly GSK Consumer Healthcare), Johnson & Johnson Consumer Inc., and Perrigo — launched a first-ever nationwide pilot program to help educate Dollar General shoppers at the shelf, using QR code technology.
Consumers scan a code that takes them to an online OTC Pain Relief Interactive Quiz, available in both English and Spanish. The quiz asks shoppers to answer a short set of questions to determine individual symptoms as well as pre-existing medical conditions such as high blood pressure, liver disease, or stomach problems to name a few. Based on the shopper’s responses, the assessment then provides a personalized report on the most appropriate pain relief products that may be right for them.
The pilot program will be available at nearly 19,000 Dollar General stores in 47 states.
“Our research showed that QR code technology is a preferred way to access information, and we believe our OTC Pain Relief Quiz is the perfect solution to help support shoppers in the pain category, given the myriad of choices available on the shelf,” says Anita Brikman, executive director of the CHPA Educational Foundation.
“As people grow more proactive about their health and well-being, manufacturers and retailers have a critical window of opportunity to address consumers’ needs by bridging health literacy gaps in a way that enables safe use and better self-care,” Brikman adds. The pilot program launched on November 6, 2022, and will continue for eight weeks through December 31, 2022.
